Abstract
Uveal melanoma is the most common primary intraocular malignant tumor in adults. Approximately
50% of patients develop metastatic disease of which greater than 90% of patients develop
hepatic metastases. Following the development of liver tumors, overall survival is
dismal with hepatic failure being the cause of death in nearly all cases. To prolong
survival for patients with metastatic uveal melanoma, controlling the growth of hepatic
tumors is essential. This article will discuss imaging surveillance following the
diagnosis of primary uveal melanoma; locoregional therapies used to control the growth
of hepatic metastases including chemoembolization, immunoembolization, radioembolization,
percutaneous hepatic perfusion, and thermal ablation; as well as currently available
systemic treatment options for metastatic uveal melanoma.
Keywords
uveal melanoma - chemoembolization - immunoembolization - radioembolization - percutaneous
hepatic perfusion
